These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 7855803

  • 1. Factor VIII concentrate: what is "high purity"?
    Schoppmann A, Weber A, Hondl F, Linnau Y.
    Thromb Haemost; 1994 Sep; 72(3):483-4. PubMed ID: 7855803
    [No Abstract] [Full Text] [Related]

  • 2. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
    Yoshioka A.
    Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
    [No Abstract] [Full Text] [Related]

  • 3. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC, Pepper DS, Griffin B.
    Thromb Haemost; 1981 Aug 28; 46(2):543-6. PubMed ID: 6795742
    [Abstract] [Full Text] [Related]

  • 4. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE.
    Biologicals; 2006 Dec 28; 34(4):281-8. PubMed ID: 16500114
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.
    Haematologica; 2003 Nov 28; 88(11):1279-83. PubMed ID: 14607757
    [Abstract] [Full Text] [Related]

  • 6. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV, Griffin B, Pepper DS, Dickson AJ, McQuillan TA, Dickson IH, Foster PR.
    Thromb Haemost; 1981 Oct 28; 46(3):597-601. PubMed ID: 6797090
    [Abstract] [Full Text] [Related]

  • 7. Development of large-scale fractionation methods. 3. Preparation of a factor VIII concentrate of intermediate-purity.
    James HL, Wickerhauser M.
    Vox Sang; 1972 Oct 28; 23(5):402-12. PubMed ID: 5077739
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel].
    Sangre (Barc); 1994 Apr 28; 39(2):157-61. PubMed ID: 8059299
    [No Abstract] [Full Text] [Related]

  • 9. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.
    Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR.
    Thromb Haemost; 1994 Feb 28; 71(2):173-9. PubMed ID: 8191394
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.
    Thromb Haemost; 1999 Feb 28; 81(2):229-33. PubMed ID: 10063997
    [Abstract] [Full Text] [Related]

  • 11. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y, Boyeldieu D, Stieltjes N.
    Nouv Rev Fr Hematol (1978); 1994 Feb 28; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [Abstract] [Full Text] [Related]

  • 12. Hemophilia--recent advances in an old disease.
    Lackner H.
    Proc Rudolf Virchow Med Soc City N Y; 1967 Feb 28; 26():28-34. PubMed ID: 5309181
    [No Abstract] [Full Text] [Related]

  • 13. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates.
    Morfini M, Rafanelli D, Filimberti E, Cinotti S, Piazza E, Longo G, Rossi Ferrini P.
    Thromb Res; 1989 Oct 15; 56(2):169-78. PubMed ID: 2515605
    [Abstract] [Full Text] [Related]

  • 14. Porcine factor VIII: past, present and future.
    Hay CR.
    Haematologica; 2000 Oct 15; 85(10 Suppl):21-4; discussion 24-5. PubMed ID: 11187865
    [Abstract] [Full Text] [Related]

  • 15. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A].
    Kunst VA, Nováková IR, Haanen C.
    Ned Tijdschr Geneeskd; 1989 Jun 10; 133(23):1163-6. PubMed ID: 2501689
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada.
    Thromb Haemost; 2002 Feb 10; 87(2):224-30. PubMed ID: 11858481
    [Abstract] [Full Text] [Related]

  • 17. High purity factor VIII and immune state in HIV.
    Nurs Stand; 2002 Feb 10; 8(3):17. PubMed ID: 8217692
    [No Abstract] [Full Text] [Related]

  • 18. [Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity].
    Gutsalo AE, Varetskaia TV, Kozulina EP, Papaian LP.
    Ukr Biokhim Zh (1978); 1995 Feb 10; 67(1):3-13. PubMed ID: 8588250
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.